grant
Understanding Immunotype, a Novel Biomarker for Checkpoint Blockade Resistance
Organization UNIVERSITY OF CONNECTICUT SCH OF MED/DNTLocation FARMINGTON, UNITED STATESPosted 10 Jul 2023Deadline 31 Dec 2028
NIHUS FederalResearch GrantFY2025AddressAntibodiesAntigensAntitumor ResponseB7-H1Biological MarkersBiopsyBloodBlood Reticuloendothelial SystemBlood SampleBlood specimenCD274CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCancer TreatmentCancersCell BodyCellsClinicalClinical DataClinical MarkersClinical OncologyClinical Treatment MoabClinical TrialsDNA mutationData SetDevelopmentEffectivenessEligibilityEligibility DeterminationFDA approvedFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFoundationsGenetic ChangeGenetic defectGenetic mutationGoalsImmuneImmune MarkersImmune systemImmunesImmunologic MarkersInferiorLeadershipLinkMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMelanoma patientMicrosatellite InstabilityMissionMonoclonal AntibodiesMorbidityMorbidity - disease rateMutationNivolumabOpdivoOutcomePD 1PD-1PD-1 blockadePD-L1PD1PD1 blockadePDL-1Patient SelectionPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPhenotypePopulationProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1Progression-Free SurvivalsProtocol ScreeningRefractoryResistanceRiskSamplingT-CellsT-LymphocyteT8 CellsT8 LymphocytesTestingTherapeuticToxic effectToxicitiesUnited StatesUrotheliumWorkaCTLA-4aCTLA-4 antibodiesaCTLA4anti-CTLA-4anti-CTLA-4 antibodiesanti-CTLA4anti-CTLA4 antibodiesanti-PD-1 blockadeanti-PD1 blockadeanti-cancer therapyanti-tumor responsebio-markersbiobankbiologic markerbiomarkerbiomarker discoverybiorepositorycancer biomarkerscancer markerscancer microenvironmentcancer therapycancer typecancer-directed therapycheck point blockadecheck point blockercheckpoint blockadecheckpoint blockersclinical biomarkersclinical developmentclinical validationclinically useful biomarkerscostdevelopmentaldisease controldisorder controlexhaustexperienceflow cytophotometrygenome mutationimmune check point blockadeimmune check point blockerimmune checkpoint blockadeimmune checkpoint blockersimmune-based biomarkersimmunogenimmunological biomarkersimmunological markersimprovedindividualized biomarkersmAbsmalignancymonoclonal Absmultidisciplinaryneoplasm/cancernew markernovelnovel biomarkernovel markerpatient oriented outcomespatients suffering from melanomapatients with melanomaperipheral bloodpersonalization of treatmentpersonalized biomarkerspersonalized medicinepersonalized therapypersonalized treatmentpharmacodynamic biomarkerpharmacodynamic markerpredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerprogrammed cell death 1programmed cell death ligand 1programmed cell death protein 1programmed cell death protein ligand 1programmed death 1prospectiveprospective testprotein death-ligand 1refractory cancerresistance mechanismresistantresistant cancerresistant mechanismresponsesle2systemic lupus erythematosus susceptibility 2thymus derived lymphocytetooltumortumor microenvironmentα-CTLA-4α-CTLA4αCTLA-4αCTLA4
Description preview
ABSTRACT
An estimated 44% of patients with cancer in the United States are eligible to receive immune checkpoint blockade
(ICB). FDA-approved ICB agents include α-PD-1 and α-CTLA-4 antibodies, but the majority of patients do not
benefit because their tumors are resistant to these agents. ICB treatment is expensive and may lead to serious
toxicity.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click